Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial

BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI, few data exist on the magnitude of platelet activation, aggregation and dosing of glycoprotein (GP) IIb/IIIa receptor inhibitors. METHODS: Sixty STEMI patients were randomised to abciximab, to hig...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Werkum, J.W., Gerritsen, W.B.M., Kelder, J.C., Hackeng, C.M., Ernst, S.M., Deneer, V.H.M., Suttorp, M.J., Rensing, B.J.W.M., Plokker, H.W.M., ten Berg, J.M.
Formato: Artigo
Idioma:Inglês
Publicado em: Bohn Stafleu van Loghum 2007
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2082085/
https://ncbi.nlm.nih.gov/pubmed/18176639
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados